<DOC>
	<DOCNO>NCT01578226</DOCNO>
	<brief_summary>Infections frequent life-threatening event patient cirrhosis , occur least 35 % hospitalized patient account 20 % inpatient death . Among cirrhotics , ascitic patient high risk death sepsis . At admission , clear-cut clinical biochemical feature helpful diagnose prognostically stratify patient sepsis . Procalcitonin ( PCT ) breakthrough marker present high sensibility specificity diagnose bacterial infection different clinical setting . The purpose study evaluate PCT diagnostic prognostic tool sepsis hospitalize cirrhotic patient ascitic decompensation .</brief_summary>
	<brief_title>Procalcitonin Cirrhotic Patients High Risk Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<criteria>liver cirrhosis regardless aetiology clinically relevant ascitic decompensation time hospital admission high haematic ascites ongoing antimicrobial therapy stop less 7 day admission last hospital discharge within 7 day surgery trauma within 30 day enrolment hepatocellular carcinoma Milan criterion extra hepatic malignancy immunodeficiency syndrome pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>Ascites</keyword>
	<keyword>Decompensation</keyword>
	<keyword>Bacterial infection</keyword>
	<keyword>Sepsis</keyword>
	<keyword>Procalcitonin</keyword>
	<keyword>PCT</keyword>
</DOC>